AtaiBeckley Inc.
ATAIA primary-source company identity page built for fast discovery, filing verification and consistent financial research.
A recent price could not be verified. Check the exchange before trading.
Four checks before any decision
Business model
Understand how the company earns and where demand originates.
Revenue and margin
Compare equivalent periods; separate growth from profitability.
Debt and cash flow
Test balance-sheet resilience and cash conversion.
Valuation and risk
Use sector peers, scenarios and explicit risk limits.
Company calendar
AtaiBeckley–Eli Lilly merger vote
AtaiBeckley shareholders will vote on the proposed merger with Eli Lilly on 8 September. Under Nasdaq's revised timetable, this is no longer the anticipated final trading day. The merger consideration is $6.75 in cash plus one contingent value right per share.
Nasdaq ↗Revised anticipated final trading day for AtaiBeckley
If the merger proceeds as planned, 10 September will be ATAI's anticipated final trading day. The shares are expected to be halted immediately after the after-hours session at about 7:50 PM ET.
Nasdaq ↗Revised anticipated closing of the AtaiBeckley–Eli Lilly merger
Subject to shareholder approval and the other closing conditions, the AtaiBeckley–Eli Lilly merger is expected to close before the market opens on 11 September. ATAI shares are expected to remain halted throughout the closing day.
Nasdaq ↗Revised anticipated suspension of AtaiBeckley trading
If the merger closes as anticipated, ATAI trading is expected to be suspended from Nasdaq effective 14 September. Holders will receive $6.75 in cash plus one contingent value right for each share.
Nasdaq ↗More NASDAQ records
Alphabetically adjacent directory records for faster navigation; this is not a peer or valuation classification.
Checking SEC financial statements
A dash means standardized data is unavailable. Always check the filing period, currency and accounting scope.